Novo Integrated Sciences (NASDAQ:NVOS) (NASDAQ: NVOS) is a development-stage life sciences company focused on advancing proprietary nanotechnology-based drug delivery products for ophthalmic and dermatological applications. Headquartered in Miami, Florida, Novo Integrated Sciences specializes in leveraging cyclodextrin-based and nanocrystal formulations designed to improve solubility, bioavailability and therapeutic efficacy of active pharmaceutical ingredients. The company’s research and development team works to optimize delivery of small-molecule drugs to targeted tissues in the eye and on the skin, addressing unmet medical needs in conditions such as dry eye, diabetic retinopathy, age-related macular degeneration and select dermatological disorders.
Since its incorporation in 1987, Novo Integrated Sciences has evolved from a general research entity into a niche biotech innovator. Early work in nutritional science and excipient technologies laid the groundwork for its current focus on ophthalmology and dermatology. Over the past decade, the company has secured multiple patent families covering its nanotechnology platforms, including inclusion complex and co-crystal approaches, and has advanced several candidates through preclinical and initial clinical studies. In addition to standalone development programs, Novo has pursued strategic collaborations to accelerate regulatory filings and commercialization pathways.
Novo Integrated Sciences conducts operations primarily in the United States, while also engaging distribution and licensing partners in Latin America, Europe and Asia to facilitate global market access. The company maintains a facility in Miami that houses research laboratories, pilot-scale manufacturing and regulatory affairs functions. Through partnerships with contract development and manufacturing organizations (CDMOs), Novo is able to scale up production of specialized formulations and work towards compliance with Good Manufacturing Practice (GMP) standards required for late-stage clinical trials and future product launches.
Under the leadership of Chairman and Chief Executive Officer Victor Catalan, Novo Integrated Sciences is guided by a management team with extensive experience in pharmaceutical R&D, regulatory strategy and business development. Mr. Catalan has over 25 years of international experience in life sciences and has overseen the company’s transition into nanotechnology-driven drug delivery. Supported by a board of directors and scientific advisors drawn from academia and industry, Novo Integrated Sciences continues to refine its pipeline, explore new therapeutic targets and prepare for potential commercial introductions of its lead candidates.
